6 completed, 4 terminated, 3 recruiting, 1 active not recruiting. 8 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 3, Completed 2, Recruiting 2, Unknown 1 |
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow BRAF Gene Mutation: new trials by email Literature Review of BRAF Gene Mutation trials Research Report on BRAF Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI - Colorectal Cancer Metastatic, Brain Metastases, Adult | Recruiting | Blokhin's Russian Cancer Research Center | 30 | 2024-04-01 | 2026-10-05 | |
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors IK-595 - Solid Tumor, Adult, Colorectal Cancer | Phase 1 | Terminated | Ikena Oncology | 75 | 2023-12-18 | 2025-09-19 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg - Metastatic Melanoma, BRAF Gene Mutation | Phase 1 | Recruiting | Rina Plattner | 30 | 2022-06-01 | 2026-02-13 |
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Ulixertinib, Physician's Choice - Advanced Solid Tumor, BRAF Gene Mutation | Phase 2 | Terminated | BioMed Valley Discoveries, Inc | 104 | 2021-01-07 | 2024-06-04 |
| Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Dabrafenib, Trametinib - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2020-01-20 | 2026-07-06 |
| Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor) - Melanoma (Skin), Melanoma Stage IIIb-IVM1a | Phase 2 | Withdrawn | TriHealth Inc. | 2019-06-24 | 2020-10-19 | |
| Continued Access to RXDX-105 RXDX-105 - Non Small Cell Lung Cancer, Ovarian Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2018-12-14 | 2025-05-15 |
| OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - Plasma circulating DNA analysis - Colorectal Cancer Metastatic, Circulating Tumor DNA | Completed | Karen-Lise Garm Spindler | 49 | 2018-06-01 | 2023-02-03 | |
| Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Dabrafenib, Trametinib - Ameloblastoma, BRAF Gene Mutation | Phase 2 | Completed | Stanford University | 1 | 2017-07-17 | 2024-01-30 |
| Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib - Melanoma, BRAF Gene Mutation | Phase 1 | Unknown | West Cancer Center | 4 | 2017-06-25 | 2020-10-12 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
| Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study - BRAF Gene Mutation, Hepatic Complication | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2013-08-23 | 2018-08-14 |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation | Completed | Intergroupe Francophone de Cancerologie Thoracique | 17664 | 2012-04-01 | 2023-07-21 | |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, BRAF Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 46 | 2012-02-06 | 2021-01-22 |
| Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies Ulixertinib (BVD-523) - Pancreatic Cancer, Small Bowel Cancer | Available | xCures | 2026-06-04 |
Carcinoma, Non-Small-Cell Lung (7) · Melanoma (6) · Thyroid Neoplasms (4) · Colorectal Neoplasms (3) · Brain Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Adamantinoma (1) · Ameloblastoma (1) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Glioma (1)
Neoplasms (13) · Neoplasms by Site (13) · Neoplasms by Histologic Type (9) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (6) · Nevi and Melanomas (6) · Skin Diseases (6)
dabrafenib (6) · trametinib (5) · talimogene laherparepvec (2) · ulixertinib (2) · 130-nm albumin-bound paclitaxel (1) · Cetuximab (1) · Crizotinib (1) · Gemcitabine (1) · Genes, mos (1) · IFL protocol (1) · Panitumumab (1) · Pharmacogenomic Testing (1) · Sorafenib (1) · Vemurafenib (1) · agerafenib (1)
Memorial Sloan Kettering Cancer Center (2) · BioMed Valley Discoveries, Inc (1) · Blokhin's Russian Cancer Research Center (1) · Deciphera Pharmaceuticals, LLC (1) · Ikena Oncology (1) · Institut de Recherches Internationales Servier (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Karen-Lise Garm Spindler (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Rina Plattner (1) · Stanford University (1) · TriHealth Inc. (1) · University of Southern California (1) · West Cancer Center (1)
United States (14) · Denmark (2) · France (2) · Australia (1) · Canada (1) · China (1) · Hong Kong (1) · Italy (1) · Japan (1) · Russia (1) · Spain (1) · United Kingdom (1)
Alexander Colevas (1) · Alexander Drilon, MD (1) · Alexey Tryakin, MD, professor (1) · Ali Bekyashev, MD, professor (1) · Anna Stroganova, MD (1) · Caroline Germa, MD (1) · Eric Sherman, MD (1) · Fabrice Barlesi, PhD, MD (1) · Filip Janku (1) · Jorge Nieva, MD (1) · Karen-Lise G Spindler (1) · Ramesh Ramanathan (1) · Rina Plattner, PhD (1) · Ruta Arays, MD (1)
2025 (1), P30CA014089 (1), P30CA015083 (1), P30CA016672 (1), R01CA258751 (1), U01CA062490 (1), U01CA069912 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186709 (1), UM1CA186716 (1), UM1CA186717 (1)